Genpharmasec Q2 revenue rises to Rs 85.66 crore on trading

Genpharmasec Limited reported consolidated revenue from operations of Rs 85.66 crore for the quarter ended September 30, 2026, up from Rs 32.64 crore a year earlier, led by Rs 81.55 crore of pharmaceutical-trading revenue. The group reported quarterly profit after tax of Rs 1.03 crore, compared with a Rs 1.18 crore loss in the corresponding quarter.

How did Genpharmasec perform in the September quarter?

Genpharmasec returned to profit in the September 30, 2026 quarter, reporting profit before tax of Rs 1.58 crore against a pre-tax loss of Rs 79.60 lakh a year earlier. Total income rose to Rs 86.72 crore from Rs 33.10 crore, with revenue from operations accounting for Rs 85.66 crore and other income contributing Rs 1.06 crore.

Total expenses increased to Rs 85.14 crore from Rs 33.90 crore in the September 2025 quarter. Purchases of stock-in-trade were Rs 74.63 crore, compared with Rs 39.78 crore a year earlier, while cost of materials consumed rose to Rs 1.69 crore from Rs 88.77 lakh and other expenses increased to Rs 3.23 crore from Rs 1.54 crore.

The group recorded total tax expense of Rs 55.02 lakh, resulting in profit after tax of Rs 1.03 crore for the quarter. In the prior-year quarter, Genpharmasec reported a loss after tax of Rs 1.18 crore; profit attributable to equity holders in the latest quarter was Rs 1.25 crore, offset by a Rs 22.30 lakh loss attributable to non-controlling interests.

What drove Genpharmasec's revenue increase?

Pharmaceutical trading was the principal driver of Genpharmasec's September-quarter revenue increase, generating Rs 81.55 crore compared with Rs 30.72 crore in the September 2025 quarter. The segment added Rs 50.83 crore year on year, while group revenue from operations increased by Rs 53.02 crore.

Laboratory testing generated Rs 4.11 crore of segment revenue, up from Rs 1.51 crore a year earlier. The two reported operating segments together totalled Rs 85.66 crore, matching consolidated revenue from operations disclosed for the quarter ended September 30, 2026.

Revenue also increased from the immediately preceding quarter. Pharmaceutical trading revenue was Rs 46.99 crore in the quarter ended June 30, 2026 and laboratory-testing revenue was Rs 2.72 crore, producing group revenue from operations of Rs 49.71 crore; the September-quarter figure was therefore Rs 35.95 crore higher.

Which Genpharmasec segments reported profits?

Pharmaceutical trading reported segment profit before interest and tax of Rs 2.82 crore in the September 2026 quarter, up from Rs 1.46 crore in the prior-year quarter. The improvement occurred alongside the segment's rise in revenue to Rs 81.55 crore from Rs 30.72 crore.

Laboratory testing remained loss-making at the segment level, reporting a loss before interest and tax of Rs 39.93 lakh, compared with a Rs 37.57 lakh loss a year earlier. Its revenue nevertheless rose by Rs 2.60 crore from the September 2025 quarter to Rs 4.11 crore.

Combined segment profit before interest and tax was Rs 2.02 crore, compared with a combined loss of Rs 57.08 lakh in the prior-year quarter. Unallocated finance cost was Rs 44.18 lakh, up from Rs 22.52 lakh, leaving reported consolidated profit before tax at Rs 1.58 crore. The filing presents segment disclosures under Indian Accounting Standard 108, the operating-segments standard.

What do Genpharmasec's half-year results show?

Genpharmasec reported revenue from operations of Rs 135.37 crore for the half year ended September 30, 2026, compared with Rs 44.68 crore in the corresponding period a year earlier. Total income was Rs 136.80 crore and total expenses were Rs 134.96 crore, resulting in profit before tax of Rs 1.84 crore.

Half-year profit after tax was Rs 85.55 lakh, compared with Rs 3.90 lakh in the half year ended September 30, 2025. Pharmaceutical trading delivered Rs 128.54 crore of half-year segment revenue, while laboratory testing contributed Rs 6.83 crore.

Net cash generated from operating activities was Rs 10.53 crore for the half year, compared with Rs 11.18 crore in the prior-year period. The cash-flow statement reported a Rs 13.66 crore reduction in trade payables, a Rs 18.87 crore increase in other current liabilities, and net cash used in financing activities of Rs 11.17 crore.

What changed in Genpharmasec's balance sheet and disposal plan?

Genpharmasec reported total assets of Rs 134.49 crore at September 30, 2026, down from Rs 138.15 crore at March 31, 2026. Total equity increased to Rs 66.48 crore from Rs 65.64 crore, while total liabilities declined to Rs 67.99 crore from Rs 72.51 crore.

The group classified assets of Rs 7.14 crore as held for sale at September 30, 2026, with directly associated liabilities of Rs 1.17 crore. The filing says the board approved a plan on November 3, 2026 to sell its entire equity stake in subsidiary Clinigenome India Private Limited, a transaction that would result in loss of control.

The disposal group is measured at the lower of carrying amount and fair value less costs to sell under Indian Accounting Standard 105, according to the filing. Depreciation and amortisation on the disposal group's non-current assets ceased from classification, and no impairment loss was recognised for the period ended September 30, 2026.

Conclusion

Genpharmasec's September-quarter outcome combined a Rs 53.02 crore year-on-year increase in revenue from operations with a move from a Rs 1.18 crore loss after tax to Rs 1.03 crore profit. Pharmaceutical trading accounted for Rs 81.55 crore of the Rs 85.66 crore quarterly revenue and Rs 2.82 crore of segment profit before interest and tax, while laboratory testing recorded a Rs 39.93 lakh segment loss.

The disclosed next event is the proposed sale of the entire stake in Clinigenome India Private Limited, for which Rs 7.14 crore of assets and Rs 1.17 crore of associated liabilities were classified as held for sale at September 30, 2026. Future disclosures on completion of the sale, its consideration and its accounting effect will clarify the change to Genpharmasec's consolidated operations.